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PURPOSE. Self-complementary AAV (scAAV) vectors have been
developed to circumvent rate-limiting second-strand synthesis
in single-stranded AAV vector genomes and to facilitate robust
transgene expression at a minimal dose. In this study, the
authors investigated the effects of intraocular injections of type
2 scAAV.GFP in mice.
METHODS. Dose–response experiments were performed to
compare conventional single-strand AAV type 2 (ssAAV2) vec-
tors with scAAV2 vectors encoding an identical expression
cassette.
RESULTS. Subretinal injection of 5  108 viral particles (vp) of
scAAV.CMV-GFP resulted in green fluorescent protein (GFP)
expression in almost all retinal pigment epithelial (RPE) cells
within the area of the small detachment caused by the injection
by 3 days and strong, diffuse expression by 7 days. Expression
was strong in all retinal cell layers by days 14 and 28. In
contrast, 3 days after subretinal injection of 5  108 vp of
ssAAV.CMV-GFP, GFP expression was detectable in few RPE
cells. Moreover, the ssAAV vector required 14 days for the
attainment of expression levels comparable to those observed
using scAAV at day 3. Expression in photoreceptors was not
detectable until day 28. Dose–response experiments confirmed
that onset of GFP expression was more rapid and robust after
subretinal injection of scAAV.CMV-GFP than of ssAAV.CMV-
GFP, resulting in pronounced expression in photoreceptors
and other retinal neurons. Similar results were obtained for
intravitreous injections.
CONCLUSIONS. These data suggest that scAAV vectors may be
advantageous for ocular gene therapy, particularly in retinal
diseases that require rapid and robust transgene expression in
photoreceptor cells. (Invest Ophthalmol Vis Sci. 2007;48:
3324–3328) DOI:10.1167/iovs.06-1306
Adeno-associated viruses (AAVs) are nonenveloped parvovi-ruses with linear, single-stranded DNA genomes that have
many characteristics that make them advantageous for use as
viral vectors.1 Although they readily infect a wide range of
nondividing human cell types with tropism determined primar-
ily by the capsid, which varies among serotypes, in humans
they are nonpathogenic, induce a moderate immune response,
and mediate long-term transgene expression. One problem
with recombinant AAV vectors in certain tissue types is de-
layed onset of transgene expression that does not reach peak
levels for up to 6 weeks.2 This can be attributed to the need for
efficient synthesis of the complementary strand of the single-
stranded vector genome before transgene expression.3
Self-complementary AAV (scAAV) vectors contain a double-
stranded vector genome generated by deletion of the terminal
resolution site (TR) from one rAAV TR, preventing the initia-
tion of replication at the mutated end. These constructs gen-
erate single-stranded, inverted-repeat genomes, with a wild-
type (wt) TR at each end and a mutated TR in the middle.4
Compared with single-strand AAV (ssAAV) vectors, scAAV vec-
tors have been shown to improve transduction efficiency in
liver,5,6 trabecular meshwork,7 and brain cells.8 In this study,
we investigated the use of scAAV vectors in the eye.
MATERIALS AND METHODS
Production of ssAAV and scAAV Vectors
Plasmids and vectors used in this study have been previously de-
scribed.4,7,8
Intraocular Injections
Mice were treated humanely in strict compliance with the ARVO
Statement for the Use of Animals in Ophthalmic and Vision Research.
Type 2 scAAV2/GFP was injected intravitreously and subretinally in
one eye, and ssAAV2/GFP was injected in the other eye with a Harvard
pump apparatus and pulled-glass micropipettes, as previously de-
scribed.9 Micropipettes were calibrated to deliver 1 L vehicle on
depression of a foot switch. For intravitreous injections, adult female
BALB/c mice were anesthetized, and, under a dissecting microscope.
The sharpened tip of a micropipette was passed through the sclera,
just behind the limbus into the vitreous cavity, and the foot switch was
depressed. Subretinal injections were performed with a condensing
lens system on the dissecting microscope and a plastic ring filled with
gonioscopic solution (Gonioscopic Prism Solution; Alcon, Fort Worth,
TX), which allowed visualization of the retina during the injection. The
pipette tip was passed through the sclera posterior to the limbus and
was positioned just above the retina. Depression of the foot switch
caused a jet of injection fluid to penetrate the retina. This technique is
atraumatic, and direct visualization allows confirmation that the injec-
tion was successful because of the appearance of a small retinal
detachment (bleb).
Flat-Mounts and Cryosections
Mice were humanely killed, and the eyes were removed and fixed with
4% paraformaldehyde in PBS for 1 hour and with 10% phosphate-
buffered formalin overnight to make flat-mounts. The cornea and lens
were removed, and the entire retina was carefully dissected from the
eyecup. Radial cuts were made from the edge to the equator of the
retina, and the retina was flat-mounted in aquamount with the photo-
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receptor facing down. Radial cuts were also made in eyecups and were
flat-mounted with the sclera facing down (choroidal flat-mounts). For
cryosections, eyes were fixed in 4% paraformaldehyde and 5% sucrose
in PBS for 1 hour and were washed with 20% sucrose in PBS overnight.
Eyes were then embedded in optimal cutting temperature embedding
compound (OCT; Miles Diagnostics, Elkhart, IN). Ocular frozen sec-
tions were rinsed in PBS and mounted with aquamount. Flat-mounts
and sections were examined by fluorescence microscopy (Axioskop
microscope; Zeiss, Thornwood, NY), and images were digitized using
a three-color charge-coupled device (CCD) video camera (IK-TU40A;
Toshiba, Tokyo, Japan) and a frame grabber.
Quantitative Comparison of Area of
Transduced Retina
Adult BALB/c mice underwent subretinal injection of 5  108 viral
particles (vp) of scAAV.GFP in one eye and 5  108 vp ssAAV.GFP in
the fellow eye. At 7, 14, and 28 days after injection, five mice were
humanely killed, and choroidal flat-mounts were examined by fluores-
cence microscopy. Images were digitized with a three-color CCD video
camera and a frame grabber. Software (Image-Pro Plus; Media Cyber-
netics, Silver Spring, MD) was used to delineate and measure the
fluorescent area per eye.
RESULTS
Subretinal Injections of Vector
Gene transfer to RPE cells and photoreceptors requires the
injection of vector into the subretinal space. Choroidal flat-
mounts were made 3 days after injection of 5  108 vp scAAV.
Green fluorescent protein (GFP) showed strong fluorescence
throughout a moderate-sized area of RPE (Fig. 1, top panel). In
fact, fluorescence intensity was saturated with 0.5 seconds of
exposure; therefore, exposure was reduced to 0.25 seconds.
Ocular sections showed that expression was limited to the RPE
and was discontinuous. At subsequent time points, widespread
strong fluorescence of the RPE was seen on choroidal flat-
mounts that required reduction of exposure time to 0.083
seconds. Ocular sections showed continuous transduction of
RPE cells at all time points, with transduction of retinal cells
ranging from focal at 7 days to strong, uniform transduction of
photoreceptors and substantial transduction of cells in the
inner retina at 28 days.
Three days after subretinal injection of 5  108 vp
ssAAV.GFP, focal areas of staining were seen on choroidal
flat-mounts (Fig. 1, top panel). Fluorescence intensity was not
saturated with 0.5 seconds of exposure but was still detectable
at 0.25 seconds; this is shown for comparison with scAAV.GFP.
Ocular sections showed occasional small areas of fluorescence
in RPE cells. At subsequent time points, choroidal flat-mounts
showed moderately sized areas of transduced RPE cells that
were smaller and less intense than those seen with scAAV.GFP.
No fluorescence was detectable after 0.083-second exposure;
hence, 0.5-second exposure images are shown. Ocular sections
showed that GFP expression in retinal cells was not detectable
until 28 days after injection and was less extensive and less
intense than that seen after injection of scAAV.GFP.
Š
FIGURE 1. Time course of GFP reporter gene expression after subreti-
nal injection of scAAV or ssAAV vectors (containing identical GFP
expression cassettes). Adult BALB/c mice underwent subretinal injec-
tion of 5  108 (top panel), 5  107 (middle panel), or 107 (bottom
panel) vp scAAV.GFP or ssAAV.GFP. Twenty mice were injected with
each dose. Results were consistent among multiple mice injected with
each dose, and images shown are representative. Choroidal flat-mounts
show a panoramic view of expression in RPE cells, providing an
assessment of the extent (area) of transduction. Exposure time in
seconds is shown in the lower-right hand corner for each image.
Transduction in the overlying retina is seen in frozen sections, for
which exposure was 0.5 seconds for all images. Onset of GFP expres-
sion occurred within days of scAAV.GFP or ssAAV.GFP expression, but
the area and intensity of expression were greater after injection of
scAAV.GFP. For both vectors, transduction of retinal cells was less
efficient and expression was delayed compared with RPE cells. Expres-
sion of GFP was seen in retinal cells 7 days after injection of 5  108
vp scAAV.GFP and 28 days after injection of 5  108 vp ssAAV.GFP.
With both, the extent and intensity of expression were greater after
injection of scAAV.GFP. Injection of 5  107 or 107 vp resulted in
uniform, strong transduction of photoreceptors for scAAV.GFP, but at
these doses ssAAV.GFP failed to demonstrate GFP expression.
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The more rapid onset and the greater overall expression of
GFP after subretinal injection of scAAV.GFP compared with
ssAAV.GFP was confirmed by dose-dilution experiments (Fig.
1, middle and bottom panels). Injection of 107 vp scAAV.GFP
resulted in rapid onset of GFP expression in RPE cells; after 28
days, strong, uniform expression was observed in photorecep-
tors (Fig. 1, bottom panel). Injection of 107 vp ssAAV.GFP
resulted in strong GFP expression in RPE cells by 28 days but
little expression in photoreceptors. No significant fluorescence
was seen after subretinal injection of 5  106 vp of either
vector.
Intravitreous Injection of Vector
Onset of GFP expression occurred within 3 days of injection of
5  108 vp scAAV.GFP and within 7 days of injection of 5 
108 vp ssAAV.GFP (Fig. 2, top panel). Although the onset of
expression was later for ssAAV.GFP, by 28 days both showed
transduction of ganglion cells and some cells in the inner
nuclear layer throughout the entire retina. Compared with the
highest dose, onset of expression was delayed after the injec-
tion of 5  107 vp scAAV.GFP, but there was still expression of
GFP in ganglion cells and some cells in the inner nuclear layer
throughout the retina, whereas GFP expression was limited to
ganglion cells after the injection of 5  107 vp ssAAV.GFP (Fig.
2, middle panel). After the injection of 107 vp, GFP intensity
was reduced compared with that in higher doses of
scAAV.GFP, but expression was still widespread in ganglion
cells and some cells in the inner nuclear layer throughout the
retina (Fig. 2, lower panel). In contrast, after injection of107 vp
ssAAV.GFP, no GFP expression was detectable before 28 days,
and then it was limited to faint expression in ganglion cells.
Quantitative Comparison of Area of
Transduced RPE/Choroid
Adult BALB/c mice underwent subretinal injection of 5  108
vp scAAV.GFP in one eye and ssAAV.GFP in the fellow eye. At
7, 14, and 28 days (n  5 at each time point) after the
injections, the area of fluorescence was measured in choroidal
flat-mounts by image analysis. At each time point, the area of
transduced RPE/choroid was significantly greater in eyes that
had been injected with scAAV.GFP than in eyes injected with
ssAAV.GFP (Fig. 3).
Retinal Histology after Injection of scAAV Vector
Hematoxylin-stained ocular frozen sections 7 or 14 days after
subretinal injection (Figs. 4a, 4b, respectively) or intravitreous
injection (Figs. 4c, 4d, respectively) of 5  108 vp scAAV.GFP
showed normal-appearing retinas with no evidence of inflam-
mation.
DISCUSSION
In this study, we have shown that compared with type 2 ssAAV
vectors, type 2 scAAV vectors result in more rapid onset of
transgene expression and greater transduction efficiency in
various cell types in the eye. Although scAAV vectors caused
modest improvement in transduction efficiency in RPE cells,
the improvement in photoreceptor cells was profound, and
Š
FIGURE 2. Time course of GFP reporter gene expression after intra-
vitreous injection of scAAV or ssAAV vectors containing identical GFP
expression cassettes. Adult BALB/c mice underwent intravitreous in-
jection of 5  108 (top panel), 5  107 (middle panel), or 107 (bottom
panel) vp scAAV.GFP or ssAAV.GFP. Twenty mice were injected with
each dose. Results were consistent among multiple mice injected with
each dose, and images shown are representative. Retinal flat-mounts
show a panoramic view of expression in the retina, providing an
assessment of the extent (area) of transduction. Exposure time in
seconds is shown in the lower right-hand corner for each image.
Transduction throughout the retina was seen in frozen sections, for
which exposure was 0.5 seconds for all images. Onset of GFP expres-
sion occurred within 3 days of injection of 5  108 vp scAAV.GFP and
within 7 days of injection of 5  108 vp ssAAV.GFP (top panel).
Although the onset of expression was later for ssAAV.GFP than for
scAAV.GFP, by 28 days both showed transduction of ganglion cells and
some cells in the inner nuclear layer throughout the entire retina.
Differences between scAAV.GFP and ssAAV.GFP in onset, extent, and
intensity of expression were accentuated at the two lower doses of
vector injected (middle and bottom panels).
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intermediate benefit was noted in other retinal cell types.
Although differences in capsid topology are likely to influence
such cell type–specific tropisms, a likely explanation is that
second-strand DNA synthesis is relatively efficient in RPE cells
compared with ganglion cells and other cells of the inner retina
and that it is inefficient in photoreceptors. This suggests that
not only will scAAV vectors be advantageous for many appli-
cations of ocular gene therapy, they will be particularly useful
for transgene expression in photoreceptors.
Our findings are consistent with those of previous studies
showing that after subretinal injection of AAV vectors, trans-
gene expression is detectable in RPE cells after approximately
1 week and gradually increases over several weeks, whereas
photoreceptor expression is substantially more delayed and
less robust.2,10 Repeated ophthalmoscopic observations after
subretinal injection of ssAAV.CMV-GFP showed that fluores-
cence was first detectable 7 days after injection, was modest
and limited in area at 13 days, and was substantially increased
by 6 weeks.2 Predominant cell types expressing GFP through
the 3-week time point were ganglion cells and RPE cells, with
minimal transduction of photoreceptor cells. Use of a murine
rhodopsin promoter to drive transgene expression in photore-
ceptors serves to partially recover expression from AAV-medi-
ated gene transfer to photoreceptors but would not be ex-
pected to improve the kinetics of expression.11 Indeed, all test
animals given subretinal injections of AAV.mOpsin.GFP
showed strong reporter gene expression in photoreceptors 6
to 8 weeks after injection, whereas at 3 weeks expression was
generally weak or below the limits of detection. The speed of
onset of expression from AAV vectors in photoreceptors can
be increased somewhat by -irradiation or other mediators of
cellular stress,10 probably through the activation of DNA repair
pathways that accelerate second-strand synthesis. The use of
scAAV vectors offers a safer and more efficient alternative to
the interventions described here.
Intravitreous injections of AAV vectors can be used to en-
hance or reduce intracellular proteins in ganglion cells or to
produce secreted proteins in ganglion cells that can have
remote effects throughout the retina. However, the enhanced
transduction efficiency of scAAV vectors demonstrates that
penetration of AAV vectors into the retinal tissue appears to be
greater than previously thought. AAV vectors are small; hence,
it is not surprising that they penetrate the retina, but internal
cell layers are exposed to lower vector concentrations than
cells at the surface. Concentrations achieved around cells
within internal layers of the retina appear to be near the limit
of detectable transduction with all but the highest intravitreous
dose (5  108) of ssAAV vector, but good transduction of deep
layers is seen with all doses of scAAV vectors. The ability to
penetrate the retina after subretinal injection might have been
less than that after intravitreous injection because, after sub-
retinal injection of the highest dose, transduction of internal
cells was seen only with scAAV and not with ssAAV. The
greater transduction of cells within the retina after intravitre-
ous injection provides another potential advantage for scAAV
vectors for applications in which retinal cells are used as
factories to produce therapeutic proteins, such as secreted
angiostatic proteins in patients with ocular neovascularization
or secreted neurotrophic factors in patients with retinal degen-
FIGURE 3. Quantitative comparison of area of retina transduced by
scAAV and ssAAV vectors over time after subretinal injection. Adult
BALB/c mice underwent subretinal injection of 5  108 vp scAAV.GFP
in one eye and ssAAV.GFP in the fellow eye. At 7, 14, and 28 days after
the injection, five mice were humanely killed, and choroidal flat-
mounts were examined by fluorescence microscopy. The area of
fluorescence was measured in each retina by image analysis, and each
point represents the mean (SEM). Mean area of fluorescence per
RPE/choroid was significantly greater after injection of scAAV.GFP at
day 7 (P  0.004183), day 14 (0.003312), and day 28 (0.043016) by
Student’s t-test.
FIGURE 4. Retinal histology after in-
jection of scAAV vector. Adult BALB/c
mice underwent subretinal (a, b) or
intravitreous (c, d) injection of 1 L of
5  108 scAAV.GFP and were hu-
manely killed 7 (a, c) or 14 (b, d) days
after injection. Ocular frozen sections
stained with hematoxylin show nor-
mal retinal histology with no evidence
of inflammation. Bars indicate 100 m.
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erations. Intravitreous injections are appealing because they
can be performed in an outpatient setting, and, if a sufficient
number of cells are transduced, a single injection may have a
therapeutic effect for months or even years. A single subretinal
injection of type 2 AAV.-actin promoter.RPE65 in dogs with
Leber congenital amaurosis resulted in recovery of electrical
activity in the retina for at least 3 years.12 In addition, the use
of scAAV vectors can facilitate studies aimed at identifying
efficacious transgenes because several models occur in neona-
tal animals requiring rapid onset of expression after vector
injection so that technically difficult and less precise intraocu-
lar injections can be avoided in utero or in newborns. Ocular
neovascularization occurs within 2 weeks of birth in mice with
oxygen-induced ischemic retinopathy13 and rho/VEGF trans-
genic mice.14 Retinal degeneration begins around postnatal
day 10 in rd1 mice.15
Gene transfer to RPE cells or photoreceptors requires sub-
retinal injection, which is a more involved but clearly feasible
surgical procedure. The use of scAAV may be particularly
valuable for gene transfer to photoreceptors, wherein the dif-
ference between gene expression achieved using scAAV or
ssAAV was profound. A disadvantage of scAAV vectors is the
more severe size limitation for expression cassettes; the cDNA
for transgenes and associated regulatory elements cannot ex-
ceed 2.5 kb, which is approximately half the allowable length
for ssAAV vectors. Therefore, it is critical to understand all
parameters of the application to decide between scAAV and
ssAAV, including target cell type, desired transgene expression
levels, size of the expression construct, and the importance of
rapid onset of expression and minimization of vector dose.
Although ssAAV vectors may be perfectly adequate or even
preferable for certain applications, the availability of scAAV
vectors clearly expands the potential applications of AAV-
mediated ocular gene therapy.
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